Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy - PubMed (original) (raw)

Clinical Trial

Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy

H J Bangstad et al. Diabetologia. 1994 May.

Abstract

We investigated in a randomized, prospective study the influence of improved blood glucose control during 2-3 years in young insulin-dependent diabetic (IDDM) patients with microalbuminuria, which is indicative of early nephropathy. Patients were randomized either to intensive treatment by continuous subcutaneous insulin infusion (CSII) (n = 9) or CT (n = 9). Kidney biopsies were taken at baseline and after 26-34 months. End points were structural changes in the glomeruli. Sensitive, quantitative, morphometric methods were used. The blood glucose control improved significantly (p = 0.01) during the study in the CSII-group as glycated haemoglobin (HbA1c) fell from 10.1% ([95% CI] 8.9-11.3) to 8.6% (7.9-9.2), but not in the CT-group, 10.1% (8.3-11.9) vs 9.7% (8.7-10.8). Mean HbA1c during the study period was significantly lower in the CSII-group than in the CT-group, 8.7% (8.1-9.3) vs 9.9% (8.5-11.3), p = 0.04. Basement membrane thickness (BMT) increased in both groups, most (CT vs CSII, p = 0.03) in the CT-group: 140 nm (50-230) vs CSII: 56 nm (27-86). In the CT-group only an increase was seen in matrix/mesangial volume fraction (p = 0.006) and matrix star volume (p = 0.04). Furthermore, a positive correlation between mean HbA1c during the study and change from baseline in BMT (r = 0.70, p = 0.001) and matrix/glomerular volume fraction (r = 0.33, p = 0.09, NS) was demonstrated. Albumin excretion rate correlated significantly to BMT and most of the matrix parameters.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Cited by

Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Lo C, et al. Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD011798. doi: 10.1002/14651858.CD011798.pub2. Cochrane Database Syst Rev. 2018. PMID: 30246878 Free PMC article. Review.
Rs12976445 Polymorphism is Associated with Risk of Diabetic Nephropathy Through Modulating Expression of MicroRNA-125 and Interleukin-6R.
Li C, Lei T. Li C, et al. Med Sci Monit. 2015 Nov 13;21:3490-7. doi: 10.12659/msm.894987. Med Sci Monit. 2015. PMID: 26563755 Free PMC article.
Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
Jha JC, Thallas-Bonke V, Banal C, Gray SP, Chow BS, Ramm G, Quaggin SE, Cooper ME, Schmidt HH, Jandeleit-Dahm KA. Jha JC, et al. Diabetologia. 2016 Feb;59(2):379-89. doi: 10.1007/s00125-015-3796-0. Epub 2015 Oct 28. Diabetologia. 2016. PMID: 26508318 Free PMC article.
Urinary excretion of neutrophil gelatinase-associated lipocalin in diabetic rats.
Arellano-Buendía AS, García-Arroyo FE, Cristóbal-García M, Loredo-Mendoza ML, Tapia-Rodríguez E, Sánchez-Lozada LG, Osorio-Alonso H. Arellano-Buendía AS, et al. Oxid Med Cell Longev. 2014;2014:961326. doi: 10.1155/2014/961326. Epub 2014 Aug 27. Oxid Med Cell Longev. 2014. PMID: 25243053 Free PMC article.
Comparative investigation of kidney mesangial cells from increased oxidative stress-induced diabetic rats by using different microscopy techniques.
Sargin AK, Can B, Turan B. Sargin AK, et al. Mol Cell Biochem. 2014 May;390(1-2):41-9. doi: 10.1007/s11010-013-1953-7. Epub 2013 Dec 29. Mol Cell Biochem. 2014. PMID: 24374793

References

1. Ann Intern Med. 1984 Oct;101(4):527-37 - PubMed
1. Kidney Int. 1992 Apr;41(4):920-3 - PubMed
1. N Engl J Med. 1993 Jul 29;329(5):304-9 - PubMed
1. Diabetes. 1979 Feb;28(2):121-5 - PubMed
1. Diabetologia. 1993 Jun;36(6):523-9 - PubMed

Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy - PubMed (original) (raw)